Posted by Michael Wonder on 12 Oct 2021
Y-mAbs’ 177Lu-omburtamab-DTPA for the treatment of patients with medulloblastoma granted rare paediatric disease designation by FDA
7 October 2021 - Y-mAbs Therapeutics today announced that the U.S. FDA has granted rare paediatric disease designation for the Company’s lutetium labelled omburtamab antibody program for the treatment of medulloblastoma.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.
